SUNNYVALE, Calif., May 1 /PRNewswire-FirstCall/ -- Accuray Incorporated , a global leader in the field of radiosurgery, today announced financial results for the fiscal third quarter ended March 31, 2007.
Total net revenues were $37.3 million for the fiscal third quarter 2007, as compared to $16.3 million for the fiscal third quarter 2006, an increase of 129 percent, and $26.3 million for the fiscal second quarter 2007, an increase of 42 percent.
For the fiscal third quarter 2007, product revenue was $29.5 million, an increase of 141 percent over the comparable period of 2006 and an increase of 53 percent over fiscal second quarter 2007.
Gross margin for the fiscal third quarter of 2007 was 59.0 percent, compared to gross margin in fiscal third quarter 2006 of 41.6 percent and gross margin in fiscal second quarter 2007 of 55.8 percent.
Operating expenses for the fiscal third quarter of 2007 were $22.9 million, compared to $14.3 million in fiscal third quarter 2006 and $22.0 million in fiscal second quarter 2007.
Total net income for the fiscal third quarter 2007 was $0.1 million, or approximately $0.00 per share, compared to a net loss of $7.7 million, or $0.48 per share, for the comparable fiscal quarter in 2006.
For the nine months ended March 31, 2007, total net revenues were $96.5 million, compared to $31.5 million for the same period in 2006, an increase of 206 percent.
The net loss for the nine months ended March 31, 2007 was $5.2 million, or $0.23 per share, compared to a net loss of $25.8 million, or $1.62 per share for the comparable period in 2006.
The Company reported that its results included stock compensation expenses of $3.7 million and $2.0 million for the fiscal quarters ended March 31, 2007 and March 31, 2006, respectively, and $8.8 million and $6.2 million for the nine months ended March 31, 2007 and March 31, 2006, respectively.
As of March 31, 2007, the Company’s total backlog, which the Company now defines as backlog under signed non-contingent contracts as well as backlog under signed contingent contracts that the Company believes have a substantially high probability of being booked as revenue, was approximately $559 million. This represents a 60 percent increase and a 9 percent increase, respectively, over total backlog computed in accordance with this definition of $350 million at March 31, 2006 and $513 million at December 31, 2006. Of the Company’s total backlog at March 31, 2007, $306 million was associated with CyberKnife System purchases and $253 million was associated with services and other recurring revenues.
Contingencies under customer contracts included in backlog include customer acceptance of the Company’s legal terms and conditions of sale, hospital board approvals, customer establishment of necessary financing or legal entities and, in certain U.S. states, government approval of a certificate of need (CON) for the operation of a radiosurgery system. On a quarterly basis, the Company will review each contingent contract to determine whether progress toward satisfaction of contingencies is sufficient to support inclusion of the contract within backlog. Going forward, it is the Company’s intention to provide information regarding total backlog in accordance with the definition described above on a quarterly basis.
At the end of the fiscal third quarter 2007, 97 CyberKnife Systems were installed at customer sites. This includes 87 systems sold directly to customers and 10 placed under shared ownership agreements. Of the 97 systems installed, 63 are in the Americas, 25 in Asia and 9 in Europe.
As of March 31, 2007, it is estimated that more than 30,000 patients have been treated with the CyberKnife System worldwide, up from an estimated 20,000 patients as of September 30, 2006. In the fiscal third quarter 2007, lung and prostate were the fastest growing clinical applications, increasing approximately 30 percent worldwide over the fiscal second quarter 2007.
“Our fiscal third quarter results demonstrate the continued recognition of the CyberKnife System as an effective treatment option for tumors anywhere in the body,” said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. “While the CyberKnife System continues to receive clinical acceptance in the treatment of brain tumors, we are experiencing rapid worldwide growth in many applications including the treatment of spine, lung and prostate tumors. The impressive growth that the CyberKnife System has gained in these applications is driven by our system’s unique ability to autonomously track, detect and correct for tumor and patient movement in real- time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy. We believe these unique capabilities combined with the momentum of our sales organization will continue to drive our success in building the market for radiosurgery.”
Earnings Call Open to Investors
Accuray will hold a conference call for financial analysts and investors today, May 1, 2007 at 2:00 p.m. PT / 5:00 p.m. ET. The conference call dial- in numbers are (800) 811-0667 (USA) or +1 (913) 981-4901 (International), Access Code: 7523746. A live webcast of the call will also be available from the Investor Relations section on the corporate Web site at http://www.accuray.com. In addition, a recording of the call will be available by calling (888) 203-1112 (USA) or +1 (719) 457-0820 (International), Access Code: 7523746, beginning at 6:00 p.m. PT / 9:00 p.m. ET, May 1, 2007. A webcast replay will also be available from the Investor Relations section of the corporate Web site at http://www.accuray.com from approximately 5:30 p.m. PT / 8:30 p.m. ET, May 1, 2007. The telephone and webcast replays will be made available for 10 days.
About Accuray
Accuray Incorporated based in Sunnyvale, Calif., is a global leader in the field of radiosurgery. Its CyberKnife System is the world’s first and only commercially available intelligent robotic radiosurgery system designed to treat tumors anywhere in the body, typically with sub- millimeter accuracy. To date, it is estimated that the CyberKnife System has been used by physicians to treat more than 30,000 patients worldwide. For more information, please visit www.accuray.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements as to financial guidance including realization of backlog, procedure growth and market acceptance, product development, clinical studies, regulatory review and approval, and commercialization of products, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward- looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: fluctuations in results of operations; reimbursement for the CyberKnife procedure; market acceptance of our products; government approvals of our products; intellectual property protection for our products; competing products; funding requirements; and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-Q for the quarterly period ended December 30, 2006, as may be updated from time to time by our other filings with the Securities and Exchange Commission. If one or more of these risks or uncertainties materialize, or if any underlying assumptions prove incorrect, our actual performance or results may vary materially from any future performance or results expressed or implied by these forward- looking statements. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
NOTE: Accuray, the Accuray logo, CyberKnife, Synchrony, Xsight and RoboCouch are among trademarks or registered trademarks of Accuray Incorporated.
Accuray Incorporated Unaudited Condensed Consolidated Statements of Operations (in thousands, except per share data) Three months ended Nine months ended March 31, March 31, March 31, March 31, 2007 2006 2007 2006 Net revenue: Products $29,515 $12,261 $75,591 $20,350 Shared ownership programs 2,437 2,145 7,248 5,860 Services 4,579 1,134 11,209 3,063 Other 809 760 2,410 2,224 Total net revenue 37,340 16,300 96,458 31,497 Cost of revenue: Costs of products 12,183 7,086 30,263 10,323 Costs of shared ownership programs 663 620 1,965 1,852 Costs of services 1,955 1,310 6,584 2,874 Costs of other 517 506 1,619 1,466 Total cost of revenue 15,318 9,522 40,431 16,515 Gross profit 22,022 6,778 56,027 14,982 Operating expenses: Selling and marketing 9,830 6,319 27,124 17,271 Research and development 6,951 4,141 19,265 13,051 General and administrative 6,100 3,852 16,855 10,239 Total operating expenses 22,881 14,312 63,244 40,561 Loss from operations (859) (7,534) (7,217) (25,579) Other income and expense 1,039 (40) 1,349 (61) Income (loss) before provision for income taxes and cumulative effect of change in accounting principle 180 (7,574) (5,868) (25,640) Provision for income taxes 62 116 185 196 Income (loss) before cumulative effect of change in accounting principle 118 (7,690) (6,053) (25,836) Cumulative effect of change in accounting principle, net of tax of $0 -- -- 838 -- Net income (loss) $118 $(7,690) $(5,215) $(25,836) Net income (loss) per common share: Basic $0.00 $(0.48) $(0.23) $(1.62) Diluted $0.00 $(0.48) $(0.23) $(1.62) Weighted average common shares outstanding used in computing net income (loss) per share: Basic 37,018 16,100 23,137 15,953 Diluted 56,234 16,100 23,137 15,953 Cost of revenue, selling and marketing, research and development, and general and administrative expenses include stock-based compensation charges as follows: Cost of revenue $398 $222 $848 $641 Selling and marketing $1,247 $627 $2,903 $1,918 Research and development $689 $407 $1,609 $1,220 General and administrative $1,350 $767 $3,412 $2,457 Accuray Incorporated Unaudited Condensed Consolidated Balance Sheets (in thousands, except share amounts) March 31, June 30, 2007 2006 (unaudited) Assets Current assets: Cash and cash equivalents $193,354 $27,856 Restricted cash -- 1 Accounts receivable, net of allowance for doubtful accounts of $20 at March 31, 2007 and June 30, 2006 15,285 11,698 Inventories 14,694 10,100 Prepaid expenses and other current assets 6,004 3,512 Deferred cost of revenue-current 25,312 4,810 Total current assets 254,649 57,977 Property and equipment, net 24,657 21,945 Goodwill 4,495 4,495 Intangible assets, net 1,252 1,446 Deferred cost of revenue and other noncurrent assets 36,892 52,760 Total assets $321,945 $138,623 Liabilities, temporary equity and stockholders’ equity (deficiency) Current liabilities: Accounts payable $13,012 $4,726 Accrued expenses 14,623 15,055 Customer advances and deferred revenue 62,200 41,979 Total current liabilities 89,835 61,760 Long-term liabilities: Customer advances and deferred revenue 111,359 130,214 Total liabilities 201,194 191,974 Temporary equity: Redeemable convertible preferred stock, no par value Authorized: 30,000,000 shares; issued and outstanding, respectively: none and 17,419,331 at March 31, 2007 and June 30, 2006 respectively; liquidation amount: none and $40,354 at March 31, 2007 and June 30, 2006 respectively. -- 27,504 Stockholders’ equity (deficiency): Preferred stock, $0.001 par value; Authorized: 5,000,000 shares and none at March 31, 2007 and June 30,2006, respectively; no shares outstanding. -- -- Common stock, $0.001 par value and no par value at March 31, 2007 and June 30, 2006, respectively; authorized: 100,000,000 and 70,000,000 shares at March 31, 2007 and June 30, 2006, respectively; issued and outstanding: 53,438,922 and 16,243,150 shares at March 31, 2007 and June 30, 2006, respectively. 53 13,276 Additional paid-in capital 246,571 43,988 Notes receivable from stockholders -- (206) Deferred stock-based compensation -- (17,272) Accumulated other comprehensive income (17) -- Accumulated deficit (125,856) (120,641) Total stockholders’ equity (deficiency) 120,751 (80,855) Total liabilities, temporary equity and stockholders’ equity (deficiency) $321,945 $ 138,623
Accuray Incorporated
CONTACT: investors, Robert McNamara, Senior Vice President and CFO,+1-408-789-4264, or investorrelations@accuray.com, or media, StephanieTomei, Accuray PR Manager, +1-408-789-4234, or stomei@accuray.com, both ofAccuray Incorporated
Web site: http://www.accuray.com//
